DCi

DCi Biotech guides global pharmaceutical, medical device and biotech companies through the complicated processes required to bring cell therapies to market. Our business advice addresses cell therapy commercialization issues, such as meeting Regulatory requirements, obtaining reimbursement, minimizing cost of goods, and optimizing clinical trial design.

Our distinctive expertise allows us to evaluate and advise on organic opportunities, as well as perform due diligence on external investments, including placements, licensing, and acquisitions. We also work with management teams to develop business plans and presentations for investors.

DCi Biotech is a unique consulting practice. It combines extensive biotech and pharmaceutical industry experience with an understanding of the science and medicine behind cell-based therapeutics—a major asset for decision makers seeking business advice in regenerative medicine.
» Read More

	March 03, 2012 Cell Therapy Reimbursement » More
	February 21, 2012 Asia Pacific Success Stories » More
	January 31, 2012 Stem Cell Research & Regen Medicine Conference » More
	October 13, 2011 Nature Biotechnology article: Engineered t-cell therapy shows efficacy in blood cancer » More
	October 01, 2011 Regenerative Medicine Online Summit » More
	June 01, 2011 Australia- Biotech Gateway » More
	April 20, 2011 Smart Surfaces and Cell Therapy Seminar » More
	March 15, 2011 Cell Therapy Business Models, Reimbursement and COGS » More
	February 14, 2011 Cell Therapy Industry Focus » More
	August 09, 2010 DCi at World Stem Cell Summit » More
	July 01, 2010 Pharma's R&D Focus Shifting to Stem Cells » More
	August 10, 2009 DCi Biotech at World Stem Cell Summit » More
	May 04, 2009 Funding and Reimbursement Sessions at ISCT 2009 » More

» News archive